GO:0072710 response to hydroxyurea: Cellular Stress Response, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072710 response to hydroxyurea describes any cellular or organismal change triggered by hydroxyurea, a ribonucleotide reductase inhibitor used clinically in sickle cell anemia, beta-thalassemia, and some dermatologic conditions.
• Hydroxyurea response involves replication stress, cell cycle arrest, and altered gene expression, but micronuclei induced by replication stress do not activate cGAS-STING.
• Clinical response to hydroxyurea is variable; pharmacokinetically guided dosing improves laboratory and clinical outcomes in young children with sickle cell anemia, and scoring tools can predict response in beta-thalassemia major.
• Proteomic profiling of plasma from beta-thalassemia patients reveals protein changes associated with hydroxyurea treatment response.
• Key genes implicated in hydroxyurea response include those involved in DNA replication, cell cycle regulation, and erythroid differentiation, though specific gene lists depend on context.
• Studying GO:0072710 requires integrated approaches such as CRISPR knockout, point mutation, knock-in, overexpression, and library screening to dissect causal genes and pathways.
Description
Hydroxyurea is a small molecule that inhibits ribonucleotide reductase, depleting deoxynucleotide pools and causing replication fork stalling. The Gene Ontology term GO:0072710, response to hydroxyurea, captures the full spectrum of cellular and organismal responses to this stimulus, from immediate signaling events to long-term changes in gene expression and physiology. This term is critical for researchers because hydroxyurea is a mainstay therapy for sickle cell anemia and beta-thalassemia, and understanding the response pathways can reveal biomarkers of efficacy and mechanisms of resistance. Moreover, hydroxyurea-induced replication stress is a valuable tool to study DNA damage responses, cell cycle checkpoints, and genome stability, with implications for cancer biology and drug development. The response to hydroxyurea is not a single linear pathway but a network of interconnected processes, including nucleotide metabolism, DNA repair, cell cycle regulation, and differentiation, making it a rich subject for functional genomics and CRISPR screening.
response to hydroxyurea At A Glance
| GO ID | GO:0072710 |
|---|---|
| GO term | response to hydroxyurea |
| Ontology | biological_process |
| Synonym | response to HU |
| Definition | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydroxyurea stimulus. |
| Major function | Cellular and organismal adaptation to hydroxyurea-induced replication stress and nucleotide depletion. |
| Related processes | DNA replication stress response, cell cycle checkpoint control, erythroid differentiation, apoptosis. |
| Clinical relevance | Hydroxyurea is used to treat sickle cell anemia and beta-thalassemia; response varies among patients. |
What Is GO:0072710?
According to the Gene Ontology, GO:0072710 response to hydroxyurea is defined as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydroxyurea stimulus. This encompasses all molecular, cellular, and physiological changes triggered by exposure to hydroxyurea, a ribonucleotide reductase inhibitor. The synonym response to HU is also used.
Why Is response to hydroxyurea Important in Cell Biology?
Understanding GO:0072710 is essential because hydroxyurea is a frontline therapy for hemoglobinopathies, and the biological response determines both efficacy and toxicity. Inter-individual variability in hydroxyurea response, as seen in beta-thalassemia major, highlights the need to identify predictive biomarkers and causal genes. In sickle cell anemia, pharmacokinetically guided dosing improves responses, suggesting that the response is dose-dependent and can be optimized. At the cellular level, hydroxyurea-induced replication stress is a model for studying genome maintenance and the consequences of micronuclei formation, which have implications for inflammation and cancer. Thus, research on this GO term bridges clinical hematology, DNA repair, and drug discovery.
• Hydroxyurea is a standard treatment for sickle cell anemia and beta-thalassemia, and response variability affects patient outcomes.
• The response to hydroxyurea involves replication stress, which can lead to micronuclei formation and genome instability.
• Hydroxyurea response pathways overlap with DNA damage response and cell cycle checkpoints, relevant to cancer therapy.
• Proteomic changes in plasma of beta-thalassemia patients receiving hydroxyurea may serve as response biomarkers.
• Hydroxyurea is also used in dermatology, e.g., for Hailey-Hailey disease, where durable responses have been observed.
• Studying GO:0072710 can reveal mechanisms of drug resistance and guide combination therapies.
• CRISPR screens can identify genes that modify hydroxyurea sensitivity, accelerating target discovery.
• Modeling hydroxyurea response in cell lines and animal models helps translate findings to clinics.
What Happens During response to hydroxyurea?
Immediate inhibition of ribonucleotide reductase and nucleotide depletion
In simple terms: Hydroxyurea blocks an enzyme needed to make DNA building blocks, causing the cell to run out of them.
Hydroxyurea directly inhibits ribonucleotide reductase, leading to decreased deoxynucleotide triphosphate pools. This depletion stalls DNA replication forks and activates the ATR-CHK1 checkpoint pathway. The resulting replication stress is a hallmark of the hydroxyurea response.
Activation of DNA damage and replication stress responses
In simple terms: The cell senses stalled replication and turns on emergency signals to protect its DNA.
Stalled forks activate ATR, which phosphorylates CHK1 and other downstream targets, leading to cell cycle arrest and DNA repair. However, micronuclei induced by hydroxyurea-induced replication stress do not activate the cGAS-STING innate immune pathway, distinguishing it from other types of DNA damage.
Transcriptional and proteomic changes
In simple terms: The cell changes which genes are turned on or off, and which proteins are made, to cope with the stress.
Hydroxyurea exposure alters gene expression programs, including upregulation of DNA repair genes, cell cycle regulators, and stress response genes. Proteomic profiling of plasma from beta-thalassemia patients treated with hydroxyurea reveals changes in proteins related to inflammation, coagulation, and erythropoiesis, which may correlate with clinical response.
Erythroid differentiation and fetal hemoglobin induction
In simple terms: In red blood cell precursors, hydroxyurea can boost production of a fetal form of hemoglobin that helps compensate for defective adult hemoglobin.
In sickle cell anemia and beta-thalassemia, hydroxyurea increases fetal hemoglobin (HbF) levels, which reduces sickling and improves anemia. The mechanism involves altered erythroid differentiation and gene expression, though the exact pathways are still under investigation.
Cellular outcomes: cell cycle arrest, apoptosis, or senescence
In simple terms: Depending on the dose and cell type, hydroxyurea can stop cell division, kill cells, or make them dormant.
The ultimate cellular response to hydroxyurea can be transient cell cycle arrest, apoptosis, or senescence. These outcomes are context-dependent and influenced by genetic background, including mutations in p53 and other tumor suppressors. In clinical settings, hydroxyurea is generally cytostatic at therapeutic doses, but cytotoxicity can occur at higher exposures.
Key Genes Involved in GO:0072710 response to hydroxyurea
The following genes and proteins are involved in the cellular response to hydroxyurea, based on their roles in nucleotide metabolism, DNA replication stress, cell cycle control, and erythroid differentiation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RRM1 | Ribonucleotide reductase subunit M1; target of hydroxyurea | Hydroxyurea directly inhibits RRM1; mutations can confer resistance. |
| RRM2 | Ribonucleotide reductase subunit M2; target of hydroxyurea | Overexpression may reduce sensitivity to hydroxyurea. |
| ATR | DNA damage sensor kinase; activated by replication stress | Mediates checkpoint response to hydroxyurea-induced stalled forks. |
| CHEK1 | Downstream effector kinase of ATR | Phosphorylated by ATR; enforces cell cycle arrest upon hydroxyurea treatment. |
| TP53 | Tumor suppressor; regulates apoptosis and cell cycle | Influences whether cells undergo apoptosis or arrest in response to hydroxyurea. |
| CDKN1A | p21; cyclin-dependent kinase inhibitor | Induced by p53; mediates cell cycle arrest after hydroxyurea. |
| HBB | Beta-globin; mutated in sickle cell anemia and beta-thalassemia | Hydroxyurea increases fetal hemoglobin, partly via altered globin gene expression. |
| HBG1 | Fetal hemoglobin gamma chain | Hydroxyurea induces HBG1 expression, contributing to HbF production. |
| BCL11A | Repressor of fetal hemoglobin | Downregulation or inhibition can mimic hydroxyurea effects on HbF. |
| GATA1 | Erythroid transcription factor | Modulates erythroid differentiation and HbF induction in response to hydroxyurea. |
| KLF1 | Erythroid transcription factor | Regulates globin gene switching; may influence hydroxyurea response. |
| MYC | Oncogene; regulates proliferation | Hydroxyurea-induced replication stress can affect MYC expression and stability. |
| RAD51 | Homologous recombination repair | Involved in repair of stalled forks caused by hydroxyurea. |
| BRCA1 | DNA repair; homologous recombination | Deficiency increases sensitivity to hydroxyurea. |
| BRCA2 | DNA repair; homologous recombination | Deficiency increases sensitivity to hydroxyurea. |
| PARP1 | Poly(ADP-ribose) polymerase; DNA repair | Inhibition synergizes with hydroxyurea in cancer cells. |
| CASP3 | Apoptosis executioner | Activated in cells undergoing hydroxyurea-induced apoptosis. |
| NFE2L2 | Oxidative stress response transcription factor | May modulate cellular response to hydroxyurea-induced oxidative stress. |
How Is response to hydroxyurea Regulated?
The response to hydroxyurea is regulated at multiple levels. At the immediate level, the ATR-CHK1 checkpoint pathway is activated by replication protein A (RPA)-coated single-stranded DNA at stalled forks, leading to cell cycle arrest. Transcriptional regulation involves p53 and other stress-responsive transcription factors that induce genes like CDKN1A and DNA repair genes. In erythroid cells, hydroxyurea-induced fetal hemoglobin production is regulated by transcription factors such as GATA1, KLF1, and BCL11A, as well as signaling pathways including JAK-STAT and MAPK. Additionally, proteomic changes in plasma suggest systemic regulation involving inflammatory and coagulation pathways. The response is also influenced by drug transporters and metabolism, which affect intracellular hydroxyurea levels.
response to hydroxyurea and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HBB | Sickle cell anemia; beta-thalassemia | Knock-in of sickle mutation (HBB E6V) in HUDEP-2 cells; response to hydroxyurea. |
| BCL11A | Fetal hemoglobin regulation; sickle cell disease | CRISPR knockout or point mutation of enhancer to mimic hydroxyurea-induced HbF. |
| RRM1 | Hydroxyurea resistance in cancer | Knockout or point mutation to assess sensitivity to hydroxyurea. |
| TP53 | Apoptosis and cell cycle arrest | Knockout in cancer cell lines to study hydroxyurea-induced cell death. |
| ATR | Replication stress response | Knockout or kinase-dead knock-in to block hydroxyurea-induced checkpoint. |
Sickle cell anemia and beta-thalassemia
Hydroxyurea is a cornerstone therapy for sickle cell anemia and beta-thalassemia, where it reduces painful crises and improves anemia by inducing fetal hemoglobin. However, response varies widely; scoring tools have been developed to predict hydroxyurea response in beta-thalassemia major patients. Pharmacokinetically guided dosing improves responses in young children with sickle cell anemia. Understanding the molecular response (GO:0072710) can identify biomarkers and optimize therapy.
Hailey-Hailey disease
Hydroxyurea has been reported to induce durable complete response in severe relapsing Hailey-Hailey disease, a rare inherited skin disorder. The mechanism may involve anti-inflammatory or immunomodulatory effects, but the cellular response to hydroxyurea in keratinocytes is not well characterized.
Cancer and replication stress
Hydroxyurea-induced replication stress is used to study DNA damage responses and genome instability. Micronuclei induced by hydroxyurea do not activate cGAS-STING, unlike micronuclei from chromosome segregation errors, which has implications for understanding immune evasion in cancer. Hydroxyurea is also used in combination therapies for myeloproliferative neoplasms and other cancers.
From response to hydroxyurea-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X mediate hydroxyurea-induced fetal hemoglobin? | CRISPR knockout of gene X in HUDEP-2 or primary erythroid cells, followed by hydroxyurea treatment. |
| Does a point mutation in RRM1 confer hydroxyurea resistance? | Point mutation knock-in of RRM1 mutation in K562 or HeLa cells, then dose-response. |
| Can overexpression of BCL11A reduce hydroxyurea response? | Overexpression of BCL11A in erythroid cells, measure HbF after hydroxyurea. |
| What is the role of ATR in hydroxyurea-induced cell cycle arrest? | Knock-in of kinase-dead ATR or knockout, followed by flow cytometry. |
| Does tagged RAD51 localize to stalled forks after hydroxyurea? | Tagged knock-in of RAD51 with GFP or HA, imaging after hydroxyurea. |
| Which genes modify hydroxyurea sensitivity in a genome-wide screen? | CRISPR library screening in a suitable cell line (e.g., K562) with hydroxyurea selection. |
How to Study the response to hydroxyurea Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify transcriptional response to hydroxyurea in erythroid cells. |
| Proteomics | Protein abundance and modifications | Discover plasma biomarkers in beta-thalassemia patients. |
| CRISPR knockout screen | Gene essentiality or sensitivity | Find genes that modify hydroxyurea cytotoxicity. |
| CRISPR activation screen | Gene overexpression effects | Identify genes whose upregulation confers resistance. |
| Flow cytometry | Cell cycle distribution, apoptosis | Quantify G2/M arrest or apoptosis after hydroxyurea. |
| Immunofluorescence | Protein localization, micronuclei | Visualize RAD51 foci or micronuclei after hydroxyurea. |
| Western blot | Protein expression and phosphorylation | Detect CHK1 phosphorylation as a marker of ATR activation. |
| qPCR | Specific gene expression | Measure HBG1 induction in erythroid cells after hydroxyurea. |
Transcriptomics (RNA-seq)
RNA sequencing can quantify global gene expression changes after hydroxyurea treatment, revealing pathways such as DNA repair, cell cycle, and erythropoiesis. This method is useful to identify candidate genes and biomarkers of response.
Proteomics
Mass spectrometry-based proteomics of cell lysates or plasma can detect protein abundance and post-translational modifications in response to hydroxyurea. For example, pharmacoproteomics profiling of plasma from beta-thalassemia patients identified proteins associated with treatment response.
CRISPR screens
Genome-wide CRISPR knockout or activation screens can identify genes that sensitize or confer resistance to hydroxyurea. These screens are powerful for discovering novel components of the response pathway and potential drug targets.
Imaging and flow cytometry
Immunofluorescence and live-cell imaging can visualize replication fork stalling, micronuclei formation, and cell cycle progression after hydroxyurea. Flow cytometry with DNA content staining or phospho-histone H3 can quantify cell cycle arrest.
How CRISPR Can Be Used to Study GO:0072710 response to hydroxyurea
Knockout
CRISPR knockout is used to delete candidate genes and assess their requirement for hydroxyurea response. For example, knocking out ATR or CHEK1 can abrogate cell cycle arrest, while knocking out RRM1 may increase sensitivity. Knockout models help establish causality.
Point Mutation
Point mutation knock-in can mimic clinically relevant variants, such as mutations in RRM1 that alter hydroxyurea binding, or in HBB that cause sickle cell disease. These models allow precise testing of drug response and resistance mechanisms.
Knock-in
Large knock-in of reporter genes or tags (e.g., GFP) at endogenous loci enables real-time monitoring of protein localization and stability after hydroxyurea. Knock-in of fetal hemoglobin gene promoters can help study HbF induction.
Overexpression
CRISPR activation or cDNA overexpression can test whether increased levels of a gene (e.g., BCL11A or RRM2) alter hydroxyurea response. Overexpression models are useful for gain-of-function studies and identifying dominant-negative effects.
How EDITGENE Supports response to hydroxyurea Research
Researchers studying response to hydroxyurea-related genes often need to determine whether a candidate gene is causally involved in the cellular response, and what its precise function is. EDITGENE provides a comprehensive suite of CRISPR services to create knockout, point mutation, knock-in, and overexpression cell models, as well as library screening and bioinformatics support, enabling rigorous functional studies of GO:0072710.
Contact EDITGENE today to design your custom CRISPR model for response to hydroxyurea research.
Frequently Asked Questions About response to hydroxyurea
What is GO:0072710 response to hydroxyurea?
GO:0072710 is a Gene Ontology biological process term defined as any process that results in a change in state or activity of a cell or an organism as a result of a hydroxyurea stimulus. It encompasses all molecular and cellular responses to hydroxyurea.
What genes are involved in response to hydroxyurea?
Key genes include RRM1 and RRM2 (targets of hydroxyurea), ATR and CHEK1 (replication stress response), TP53 and CDKN1A (cell cycle arrest), and HBB, HBG1, BCL11A (erythroid differentiation and fetal hemoglobin induction).
How does hydroxyurea work at the cellular level?
Hydroxyurea inhibits ribonucleotide reductase, depleting deoxynucleotides and stalling DNA replication forks. This activates the ATR-CHK1 checkpoint, leading to cell cycle arrest and changes in gene expression.
Why do some patients not respond to hydroxyurea?
Response variability may be due to genetic polymorphisms in drug metabolism, transporters, or downstream pathway genes. Scoring tools can predict response in beta-thalassemia major.
What diseases are treated with hydroxyurea?
Hydroxyurea is used for sickle cell anemia, beta-thalassemia, some myeloproliferative neoplasms, and has been reported for Hailey-Hailey disease.
Can CRISPR be used to study hydroxyurea response?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of genes involved in the response to hydroxyurea.
What is the role of ATR in hydroxyurea response?
ATR is a kinase that senses stalled replication forks caused by hydroxyurea and activates CHK1, leading to cell cycle arrest and DNA repair.
Does hydroxyurea induce micronuclei?
Yes, hydroxyurea-induced replication stress can lead to micronuclei formation, but these micronuclei do not activate cGAS-STING.
How is hydroxyurea response measured in the lab?
Common methods include RNA-seq, proteomics, flow cytometry for cell cycle, immunofluorescence for DNA damage markers, and CRISPR screens.
What is the clinical importance of hydroxyurea response?
Understanding the response can improve dosing, predict efficacy, and reveal resistance mechanisms, ultimately optimizing treatment for hemoglobinopathies.
Conclusion
GO:0072710 response to hydroxyurea is a broad biological process that integrates nucleotide metabolism, DNA replication stress, cell cycle control, and erythroid differentiation. Its clinical relevance spans sickle cell anemia, beta-thalassemia, and other conditions, where hydroxyurea remains a key therapeutic. Continued research using CRISPR models and multi-omics approaches will uncover the genetic and molecular determinants of response, paving the way for personalized medicine.
References
- 3. Ansari SH et al.. 2022. A Pragmatic Scoring Tool to Predict Hydroxyurea Response Among β-Thalassemia Major Patients in Pakistan.. J Pediatr Hematol Oncol 44(1):e77-e83 PMID: 33710118
- 4. Takaki T et al.. 2024. Micronuclei induced by radiation, replication stress, or chromosome segregation errors do not activate cGAS-STING.. Mol Cell 84(11):2203-2213.e5 PMID: 38749421
- 6. McGann PT et al.. 2019. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.. Am J Hematol 94(8):871-879 PMID: 31106898
- 7. Dasanu CA. 2024. Severe Relapsing Hailey-Hailey Disease Displaying a Durable Complete Response to Hydroxyurea.. Acta Dermatovenerol Croat 32(3):168-169 PMID: 40654217
- 8. Zohaib M et al.. 2019. Pharmacoproteomics Profiling of Plasma From β-Thalassemia Patients in Response to Hydroxyurea Treatment.. J Clin Pharmacol 59(1):98-106 PMID: 30152032
